Literature DB >> 17052870

Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation.

Herbert Chiou1, Li Li, Tingting Hu, Hak-Kim Chan, Jian-Feng Chen, Jimmy Yun.   

Abstract

The purpose of this study was to produce salbutamol sulfate (SS) as a model anti-asthmatic drug using high-gravity controlled precipitation (HGCP) through antisolvent crystallisation. An aqueous solution of SS was passed through a HGCP reactor with isopropanol as antisolvent to induce precipitation. Spray drying was employed to obtain dry powders. Scanning electron microscopy, X-ray powder diffraction (XRD), density measurement, thermal gravimetric analysis, and dynamic vapour sorption were carried out to characterise the powder physical properties. The aerosol performance of the powders was measured using an Aeroliser connected to a multiple stage liquid impinger operating at 60 L/min. The HGCP SS particles were elongated with 0.1 microm in width but varying length of several mum, which formed spherical agglomerates when spray dried. The particles showed the same XRD pattern and true density (1.3g/cm3) as the raw material, indicating that they belonged to the same crystalline form. However, the spray dried agglomerates had a much lower tapped density (0.1g/cm3) than the raw material (0.6g/cm3). Compared with the powder obtained by spray drying directly from an aqueous solution, the SS powders obtained from HGCP were much less hygroscopic (0.6% versus 10% water uptake at 90% RH). The in vitro aerosol performance showed a fine particle fraction FPFloaded and FPFemitted up to 54.5+/-4.9% and 71.3+/-10.0%, respectively. In conclusion, SS powder with suitable physical and aerosol properties can be obtained through antisolvent HGCP followed by spray drying.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052870     DOI: 10.1016/j.ijpharm.2006.09.022

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Authors:  Philip Chi Lip Kwok; Amolnat Tunsirikongkon; William Glover; Hak-Kim Chan
Journal:  Pharm Res       Date:  2010-12-07       Impact factor: 4.200

2.  Engineering of crystalline combination inhalation particles of a long-acting beta2-agonist and a corticosteroid.

Authors:  Chonladda Pitchayajittipong; Jagdeep Shur; Robert Price
Journal:  Pharm Res       Date:  2009-09-26       Impact factor: 4.200

3.  Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.

Authors:  Nashwa El-Gendy; Warangkana Pornputtapitak; Cory Berkland
Journal:  Eur J Pharm Sci       Date:  2011-09-21       Impact factor: 4.384

Review 4.  Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability.

Authors:  Maria Rosa Gigliobianco; Cristina Casadidio; Roberta Censi; Piera Di Martino
Journal:  Pharmaceutics       Date:  2018-08-21       Impact factor: 6.321

5.  Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets.

Authors:  Yudong Shen; Xingya Li; Yuan Le
Journal:  Pharmaceutics       Date:  2018-09-11       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.